National Bank of Canada FI Increases Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

National Bank of Canada FI grew its stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 45.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,216 shares of the medical research company's stock after purchasing an additional 6,627 shares during the quarter. National Bank of Canada FI's holdings in Charles River Laboratories International were worth $4,179,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Oregon Public Employees Retirement Fund increased its position in Charles River Laboratories International by 1.0% during the second quarter. Oregon Public Employees Retirement Fund now owns 4,424 shares of the medical research company's stock worth $914,000 after acquiring an additional 45 shares during the period. Empirical Finance LLC increased its holdings in shares of Charles River Laboratories International by 4.2% during the third quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company's stock worth $258,000 after purchasing an additional 53 shares during the period. American Trust raised its position in shares of Charles River Laboratories International by 5.9% in the second quarter. American Trust now owns 976 shares of the medical research company's stock valued at $202,000 after buying an additional 54 shares in the last quarter. Tortoise Investment Management LLC boosted its stake in shares of Charles River Laboratories International by 77.0% in the second quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company's stock valued at $27,000 after buying an additional 57 shares during the period. Finally, OLD National Bancorp IN grew its position in Charles River Laboratories International by 3.1% during the third quarter. OLD National Bancorp IN now owns 1,988 shares of the medical research company's stock worth $392,000 after buying an additional 59 shares in the last quarter. Institutional investors own 98.91% of the company's stock.

Analyst Ratings Changes

Several equities analysts have commented on CRL shares. Bank of America decreased their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating on the stock in a report on Friday. Redburn Atlantic initiated coverage on Charles River Laboratories International in a report on Monday, October 14th. They issued a "sell" rating and a $151.00 target price on the stock. UBS Group boosted their price target on Charles River Laboratories International from $240.00 to $250.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. Robert W. Baird reduced their price objective on Charles River Laboratories International from $191.00 to $190.00 and set a "neutral" rating on the stock in a research note on Friday, September 20th. Finally, Citigroup downgraded Charles River Laboratories International from a "neutral" rating to a "sell" rating and lowered their target price for the stock from $215.00 to $175.00 in a research note on Tuesday, October 1st. Three equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, Charles River Laboratories International currently has a consensus rating of "Hold" and a consensus target price of $214.00.

Insider Activity

In related news, Director Richard F. Wallman sold 6,621 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the sale, the director now owns 12,386 shares of the company's stock, valued at approximately $2,676,862.32. The trade was a 34.83 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Stock Down 2.0 %

NYSE:CRL traded down $3.81 on Friday, hitting $190.46. The stock had a trading volume of 546,297 shares, compared to its average volume of 615,935. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. Charles River Laboratories International, Inc. has a 52 week low of $176.48 and a 52 week high of $275.00. The business's fifty day moving average is $194.36 and its 200 day moving average is $203.28. The company has a market cap of $9.74 billion, a PE ratio of 23.92, a P/E/G ratio of 5.00 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, topping analysts' consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $975.99 million. During the same period in the previous year, the company posted $2.72 EPS. The company's revenue for the quarter was down 1.6% on a year-over-year basis. On average, equities research analysts expect that Charles River Laboratories International, Inc. will post 10.18 EPS for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).